p38 mitogen-activated protein kinase pathway is involved in protein kinase Cα-regulated invasion in human hepatocellular carcinoma cells

Cancer Research

Volumn 67, Issue 9, 2007, Pages 4320-4327

  Hsieh, Yi Hsien ^a   Wu, Trang Tiau ^a   Huang, Chih Yang ^b   Hsieh, Yih Shou ^a   Hwang, Jin Ming ^a   Liu, Jer Yuh ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE C ALPHA; STRESS ACTIVATED PROTEIN KINASE 1;

ARTICLE; CARCINOMA CELL; CELL CLONE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; ENZYME ACTIVATION; HUMANS; LIVER NEOPLASMS; MAP KINASE KINASE 6; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDES, ANTISENSE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE C-ALPHA; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 34249314755     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2486     Document Type: Article

References (42)

1. Nakashima S. Protein kinase Cα (PKCα): regulation and biological function. J Biochem (Tokyo) 2002;132:669-75.
2. Lahn M, Kohler G, Sundell K, et al. Protein kinase Cα expression in breast and ovarian cancer. Oncology 2004;67:1-10.
3. Ways DK, Kukoly CA, DeVente J, et al. MCF-7 breast cancer cells transfected with PKC-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 1995;95:1906-15.
4. Ahmad S, Glazer RI. Expression of the antisense cDNA for protein kinase C α attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol 1993;43:858-62.
5. Mandil R, Ashenazi E, Blass M, et al. Protein kinase Cα and protein kinase Cδ play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res 2001;61:4612-9.
6. Wang XY, Repasky E, Liu HT. Antisense inhibition of protein kinase Cα reverses the transformed phenotype in human lung carcinoma cells. Exp Cell Res 1999;250:253-63.
7. Jiang XH, Tu SP, Cui JT, et al. Antisense targeting protein kinase C α and β1 inhibits gastric carcinogenesis. Cancer Res 2004;64:5787-94.
8. Koivunen J, Aaltonen V, Koskela S, et al. Protein kinase Cα/β inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res 2004;64:5693-701.
9. Liu B, Maher RJ, Hannun YA, Porter AT, Honn KV. 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKCα. J Natl Cancer Inst 1994;86:1145-51.
10. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003;22:395-403.
11. Webb CP, Van Aelst L, Wigler MH, Woude GF. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci U S A 1998;95:8773-8.
12. Amundadottir LT, Leder P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 1998;16:737-46.
13. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-2.
14. Vicent S, Garayoa M, Lopez-Picazo JM, et al. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 2004;10:3639-49.
15. Uzgare AR, Kaplan PJ, Greenberg NM. Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 2003;55:128-39.
16. Davidson B, Konstantinovsky S, Kleinberg L, et al. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol 2006;102:453-61.
17. Wang Q, Ding Q, Dong Z, Ehlers RA, Evers BM. Down-regulation of mitogen-activated protein kinases in human colon cancers. Anticancer Res 2000;20:75-83.
18. Hardwick JC, van den Brink GR, Offerhaus GJ, van Deventer SJ, Peppelenbosch MP. NF-κB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 2001;20:819-27.
19. Pomerance M, Quillard J, Chantoux F, Young J, Blondeau JP. High-level expression, activation, and subcellular localization of p38-MAP kinase in thyroid neoplasms. J Pathol 2006;209:298-306.
20. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 1998;18:790-8.
21. Xu L, Chen S, Bergan RC. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 2006;25:2987-98.
22. Shin I, Kim S, Song H, Kim HR, Moon A. H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem 2005;280:14675-83.
23. Nakajima K, Tohyama Y, Kohsaka S, Kurihara T. Protein kinase Cα requirement in the activation of p38 mitogen-activated protein kinase, which is linked to the induction of tumor necrosis factor α in lipopolysaccharide- stimulated microglia. Neurochem Int 2004;44:205-14.
24. Hsieh YH, Wu TT, Tsai JH, Huang CY, Hsieh YS, Liu JY. PKCα expression regulated by Elk-1 and MZF-1 in human HCC cells. Biochem Biophys Res Commun 2006;339:217-25.
25. Chang JT. An economic and efficient method of RNAi vector constructions. Anal Biochem 2004;334:199-200.
26. Sobottka SB, Berger MR. Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties. Cancer Chemother Pharmacol 1992;30:385-93.
27. Saurin JC, Fallavier M, Sordat B, Gevrey JC, Chayvialle JA, Abello J. Bombesin stimulates invasion and migration of Isrecol colon carcinoma cells in a Rho-dependent manner. Cancer Res 2002;62:4829-35.
28. Shen L, Dean NM, Glazer RI. Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Cα antisense oligonucleotide. Mol Pharmacol 1999;55:396-402.
29. Bennett CF, Cowsert LM. Antisense oligonucleotides as a tool for gene functionalization and target validation. Biochim Biophys Acta 1999;1489:19-30.
30. Raingeaud J, Gupta S, Rogers JS, et al. Proinflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995;270:7420-6.
31. Koochekpour S, Sartor O, Hiraiwa M, et al. Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells. Asian J Androl 2005;7:147-58.
32. Brancho D, Tanaka N, Jaeschke A, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003;17:1969-78.
33. Honma N, Genda T, Matsuda Y, et al. MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. Lab Invest 2006;86:687-96.
34. 2-terminal kinase pathway is involved in constitutive matrix metalloproteinase-1 expression in a hepatocellular carcinoma-derived cell line. Int J Cancer 2004;109:867-74.
35. Wang XS, Diener K, Manthey CL, et al. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem 1997;272:23668-74.
36. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem 1998;273:1741-8.
37. Hwang ES, Lee HJ. Allyl isothiocyanate and its N-acetylcysteine conjugate suppress metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in SK-Hep 1 human hepatoma cells. Exp Biol Med 2006;231:421-30.
38. Wen-Sheng W. Protein kinase Cα trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2. Cancer Lett 2006;239:27-35.
39. Mauro A, Ciccarelli C, De Cesaris P, Scoglio A, Bouche M, Molinaro M. PKCα-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells. J Cell Sci 2002;115:3587-99.
40. Kim KY, Kim BC, Xu Z, Kim SJ. Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-β-induced apoptosis in hepatoma cells. J Biol Chem 2004;279:29478-84.
41. Iyoda K, Sasaki Y, Horimoto M, et al. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 2003;97:3017-26.
42. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003;63:1684-95.